'We think that the short, heated and not very well informed debate in the Parliament did not do justice to the responsibility that a democratic society has towards its future generations' May 11, 2012 Prof. Parvin Sinclair Director NCERT Subject: Resignation as Chief Advisers ( Pol Sc) Dear Professor Sinclair, We have followed the discussion in both Houses of the Parliament today regarding the cartoons published in the NCERT's Political Science Textbooks. We also heard the...

-The Hindu Business Line The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land. The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that “invisible hands” of drug-makers were involved in getting favourable reports on medicines...

Doctors across India who encounter patients with tuberculosis will have to disclose the identity, age, sex, and address of each patient to local health authorities under an order issued this week by the Union health ministry. The health ministry said today that it is essential to have complete information as part of its efforts to ensure that patients receive proper diagnosis and therapy and to curb the emergence and spread of...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...